Intratumoral SD-101
Total Payments
$4.5M
Transactions
418
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $997,077 | 131 | 0 |
| 2019 | $2.7M | 203 | 0 |
| 2018 | $823,061 | 84 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.5M | 418 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Dynavax Technologies Corporation | $4.5M | 0 |
Top Doctors Receiving Payments for Intratumoral SD-101
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Birmingham, AL | $4.5M | 418 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.5M
- Total Doctors 0
- Transactions 418
About Intratumoral SD-101
Intratumoral SD-101 is a drug associated with $4.5M in payments to 0 healthcare providers, recorded across 418 transactions in the CMS Open Payments database. The primary manufacturer is Dynavax Technologies Corporation.
Payment data is available from 2018 to 2020. In 2020, $997,077 was paid across 131 transactions to 0 doctors.
The most common payment nature for Intratumoral SD-101 is "Unspecified" ($4.5M, 100.0% of total).
Intratumoral SD-101 is associated with 1 research study, including "A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma" ($4.5M).